Researchers led by LMU’s Professor Angelika Vollmar and Professor Stephan Sieber of the Technische Universit�t M�nchen have identified a class of chemicals that represent a potential new weapon in the fight against malignant tumors. The compound is itself non-toxic, but it stimulates the killing of rapidly dividing cells by chemotherapeutic drugs. …
“When chemotherapy is administered after the first trimester of pregnancy, we cannot discern any problems in the children,” says lead author Dr Frederic Amant, KU Leuven and University Hospitals Leuven in Belgium. “Fear about the risks of chemotherapy administration should not be a reason to terminate a pregnancy, delay cancer treatment for the mother, or to deliver a baby prematurely.” Concerns about the potential impact of cancer treatment on unborn children has until recently left some oncologists hesitant to administer treatments to pregnant cancer patients, says Amant. To address these concerns, his group has led three new studies presented at ESMO 2014. …
The aim of the research was to develop an improved tyrosine kinase inhibitor that is actually inactive and which is only activated selectively in the malignant tissue. This is intended to prevent damage to healthy tissue and therefore minimise side effects for patients. As part of the paper published in the journal Angewandte Chemie [Applied Chemistry], International Edition, a new inhibitor has been successfully synthesised and coordinated to cobalt(III). …
Vaccines authorized for the German market are targeted against HPV types 16 and 18 because these are two of the most common high-risk types in Germany. …
Radiation therapy is standard of care for some patients with thoracic malignancies such as lung cancer, esophageal cancer, thymoma, or malignant mesothelioma. …
It is estimated that 2,700 Canadian women will be diagnosed with ovarian cancer in 2014 and that 1,750 Canadian women will die from the disease, according to Ovarian Cancer Canada. This cancer is often diagnosed late and develops a resistance to chemotherapy. “What we’ve discovered will help clinicians to better treat women with ovarian cancer,” says Dr. Ben Tsang, senior scientist at the Ottawa Hospital Research Institute and professor at the University of Ottawa…
The study examined the patient-reported outcomes of 91 men with prostate cancer who received MRI-guided, vessel-sparing radiation at University of Michigan Providence Cancer Institute. The vessel-sparing radiation technique limits the amount of radiation to critical erectile tissues using MRI scans to identify the blood vessels responsible for erections. …
The phase I/II trial enrolled 343 patients with low-to-intermediate risk prostate cancer at five institutions from 2002 to 2010 to study the effectiveness of HPFX RT, as well as the patients’ ability to tolerate the treatment. …
GIS’s DNA analysistechnique has allowed the researchers to further study the biology of Opisthorchis viverrini to understand the cause and the eventual development of treatments for bile duct cancer, a condition caused by the parasite. The breakthrough was published in the scientific journal Nature Communications. Opisthorchis viverrini is a trematode that infects millions in Asia, and it is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). …
The research, presented at the European Respiratory Society (ERS) International Congress in Munich, suggests that testing the temperature of breath could be a simple and noninvasive method to either confirm or reject the presence of lung cancer. Many research teams have been looking at the possibility of using breath tests for a number of cancers. This is the first study looking at breath temperature as a marker in lung cancer. The researchers enrolled 82 people in the study who had been referred for a full diagnostic test after an x-ray suggested the presence of lung cancer…